Keeping Track: Terlipressin Falls Short Of US FDA Approval; Novel NDAs From Pfizer And Apellis; New BTDs For Sanofi, BeyondSpring

 
• By Bridget Silverman
  
Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers